Drug intelligence / Profile preview

Hemay028

Development stage: Phase 1
Lead developer: Tianjin Hemay Biotech
Modality: Small Molecules
Administration: Topical

Overview

**Hemay028** is a small-molecule **phosphodiesterase 4 (PDE4) inhibitor** developed by **Tianjin Hemay Pharmaceutical** (also referred to as Tianjin Hemay Oncology Pharmaceutical Co., Ltd. or Tianjin Hemei Biological Technology Co., Ltd.) for dermatological indications. It is formulated as **Hemay808**, a topical ointment, and has been investigated in Phase I and Phase II clinical trials for **atopic dermatitis**, with the Phase II trial (NCT04352595) evaluating efficacy and safety in patients.[1][9][11][14][15]

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on Hemay028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemay028.

Explore the full profile